license suspended, Canadian Broadcasting Corporation (2023) Personal importation, Food and Drug Administration (2024) Save on Ozempic (semaglutide) injection, Novo Nordisk FDAs concerns with unapproved GLP-1 drugs used for weight loss, Food & Drug Administration (2025) Internet pharmacy warning letters, Food & Drug Administration (2025) How to buy medicines safely from an online pharmacy, Food & Drug Administration (2025) Supply of Ozempic and other GLP-1 receptor agonists: Notice, Government of Canada (2024) FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, Food & Drug Administration (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
GLP-1 users should avoid meals and snacks that are deep-fried, high in sugar or saturated fat, and spicy or acidic, since those foods can worsen side effects and work against weight-loss efforts, Snashall said
Clinicians should inform patients and families of this risk before initiating treatment, particularly in individuals with psychiatric or substance use comorbidities
This post examines why the approval matters, how small-molecule GLP-1 agonists compare with peptides, and what the shift means for patent strategy and the pipeline ahead